PRESSRELEASE
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
-
ACI-125891 delivers the primary factor of a precision medication method by enabling early and correct analysis of a-syn pathology in sure ailments
-
Clinical trial of ACI-12589 confirmed a selected and reproducible retention sample in sufferers with MSA, a uncommon and difficult-to-diagnose neurodegenerative illness
-
ACI-12589 guarantees to catalyze accelerated growth and focused therapy of MSA and different a-synucleinopathies equivalent to genetic Parkinson’s illness (PD)
Lausanne, Switzerland, October 27, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical firm pioneering precision medication for neurodegenerative ailments, at the moment introduced the publication of a peer-reviewed paper in Nature Communications exhibiting the power of an alpha-synuclein (a-syn) positron emission tomography (PET) tracer to determine sufferers with a number of system atrophy (MSA).
The scientific trial of AC Immune’s wholly owned experimental a-syn PET tracer ACI-12589 was led by the workforce of Oskar Hansson MD, PhD, at Lund University and Skåne University Hospital, in collaboration with associates at InviCRO LLC, with the assist of a grant from The Michael J. Fox Foundation (MJFF) for Parkinson’s Research.
The Nature Communications paper describes the first-in-human trial of ACI-12589 evaluating wholesome management topics to sufferers with a-synucleinopathies and different neurological diagnoses. It concludes that ACI-12589 confirmed a selected and reproducible retention sample in sufferers with MSA, indicating that the PET tracer might allow earlier, extra correct analysis of MSA and probably, extra exact monitoring of illness development and responses to new a-syn focused therapeutics in growth.
Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We are proud to have this paper showing the first-ever live images of a-syn in a living human brain published in the prestigious peer-reviewed journal, Nature Communications. The data demonstrate that ACI-12589 could be an important diagnostic tool to identify, characterize and track the progression of a-syn pathology in MSA and evaluate the impact of therapeutic interventions. As the first imaging agent for a-syn, ACI-12589 represents a major step towards achieving AC Immune’s ambition of developing precision medicine for neurodegenerative diseases. We are grateful to our talented collaborators at Lund University and Skåne University Hospital and the MJFF for its continuing support for this important work.”
Dr. Marie Kosco-Vilbois, Chief Scientific Officer of AC Immune, added: “Accurately detecting a-syn in the living brains of patients is paramount, particularly in view of the challenges of diagnosing the serious diseases related to pathological a-synuclein aggregates. We are encouraged by this first success in MSA and look forward to expanding the potential clinical applications of this tracer, and others emerging from the AC Immune platform.”
1 For PET imaging, ACI-12589 is radiolabeled with 18F, denoted as [18F]ACI-12589
About AC Immune’s a-synuclein PET tracer program
AC Immune is at present evaluating the usage of [18F]ACI-12589 in longitudinal research for MSA, and for the detection of a-syn in different ailments equivalent to genetic PD. Further building on this success, the Company is creating extra a-syn PET tracers for Parkinson’s illness (PD) utilizing its Morphomer® know-how platform. It is anticipated that these will enter scientific growth within the very close to future.
About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical firm that goals to grow to be a worldwide chief in precision medication for neurodegenerative ailments, together with Alzheimer’s illness, Parkinson’s illness, and NeuroOrphan indications pushed by misfolded proteins. The Company’s two clinically validated know-how platforms, SupraAntigen® and Morphomer®, gas its broad and diversified pipeline of first- and best-in-class property, which at present options sixteen therapeutic and diagnostic packages, 5 of that are at present in Phase 2 scientific trials and considered one of which is in Phase 3. AC Immune has a robust observe report of securing strategic partnerships with main international pharmaceutical firms together with Genentech, a member of the Roche Group, Eli Lilly and Company, and others, leading to substantial non-dilutive funding to advance its proprietary packages and >$3 billion in potential milestone funds.
SupraAntigen® is a registered trademark of AC Immune SA within the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.
The info on our web site and another web sites referenced herein is expressly not integrated by reference into, and doesn’t represent part of, this press launch.
For additional info, please contact:
Forward wanting statements
This press launch incorporates statements that represent “forward-looking statements” inside the which means of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements apart from historic reality and will embody statements that handle future working, monetary or business efficiency or AC Immune’s methods or expectations. In some instances, you’ll be able to determine these statements by forward-looking phrases equivalent to “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and different comparable terminology. Forward-looking statements are based mostly on administration’s present expectations and beliefs and contain vital dangers and uncertainties that might trigger precise outcomes, developments and business choices to vary materially from these contemplated by these statements. These dangers and uncertainties embody these described underneath the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and different filings with the Securities and Exchange Commission. Forward- wanting statements communicate solely as of the date they’re made, and AC Immune doesn’t undertake any obligation to update them in mild of latest info, future developments or in any other case, besides as could also be required underneath relevant legislation. All forward-looking statements are certified of their entirety by this cautionary assertion.
Attachment
